_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
It is the first branded generic alternative to Fostair 100/6 pMDI
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
The group has a total of 320 ANDA approvals
The company has tied up with OrbiMed as a financial partner for global reach
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Innovative solutions and a deep understanding of the market makes this a unique combination
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
Subscribe To Our Newsletter & Stay Updated
